In mouse lymphoma and solid tumour models, blockade of PD-1 can enhance CD4+ T cell-mediated anti-tumour immunity and in NSCLC patients, CD4+ immunity was required for clinical responses to PD-1/PDL-1 blockade therapy25,26. This evidence concerns the gene CD274 and neoplasm.